Search results for "Therapeutic targeting"
showing 4 items of 4 documents
Novel cytokine-targeted therapies and intestinal inflammation
2009
Several cytokines have been identified as critical mediators of chronic inflammation in inflammatory bowel disease (IBD) and biological therapies that target these molecules have been developed during recent years. Thereby, anti-TNF agents have noticeably improved the treatment of patients with IBD in comparison to conventional therapy. Furthermore, initial clinical trials showed promising results with anti-IL-6 and anti-IL-12/IL-23 agents. In addition to these well-known mediators of IBD, various novel cytokines have been described as critical during the pathogenesis of IBD in recent experimental studies and therapeutic targeting of these cytokines could provide new strategies for human di…
Therapeutic targeting of SNAIL, RKIP, and YY1 in tumor metastasis and drug resistance
2020
Abstract Cancer is the leading cause of deaths worldwide and is of great importance. Metastasis-inducing the majority of cancer related deaths is a principal problem in cancer treatment. Therefore, therapy regimes preventing metastasis formation are of prominent importance to improve the outcome of malignant diseases. The epithelial-mesenchymal transition (EMT) is a predominant process associated with the onset of metastasis and converts epithelial cells to mesenchymal cells. In this chapter, we concentrated on three proteins involved in the metastasis and EMT: RKIP, SNAIL, and YY1. Briefly, SNAIL and YY1 are overexpressed in many cancers, while RKIP is downregulated. Therefore, these prote…
A novel rationale for targeting FXI: Insights from the hemostatic microRNA targetome for emerging anticoagulant strategies
2021
Therapeutic targeting of blood coagulation is a challenging task as it interferes with the delicate balance of pro- and anticoagulant activities. Anticoagulants are employed in millions of thrombophilic patients worldwide each year. The treatment and prevention of venous thromboembolism has changed drastically. Traditional vitamin K antagonists are being replaced by direct oral anticoagulants (DOACs), which selectively target coagulation factors Xa or IIa. However for a growing population with comorbidities satisfying therapeutic options are still lacking and the quest for novel therapeutics continues. Recently, targeting factors XI or XII have emerged as new therapeutic strategies. As thes…
A novel rationale for targeting FXI: Insights from the hemostatic miRNA targetome for emerging anticoagulant strategies
2018
Abstract The treatment and prevention of thrombosis is currently under a period of rapid change with the replacement of traditional anticoagulant vitamin K antagonists, which impair the biosynthesis of a wide range of blood coagulation factors, with direct oral anticoagulants (DOACs), which specifically target factors FXa or FIIa. Nevertheless therapeutic targeting of blood coagulation is an inherently difficult task as it interferes with the delicate balance of pro- and anticoagulant activities. Although anticoagulants are employed in millions of thrombophilic patients worldwide each year, for a growing population with comorbidities who exhibit an increased risk of bleeding with DOAC treat…